Policy
Some 200 rare disease therapies are at risk of losing eligibility for a pediatric priority review voucher, a recent analysis by the Rare Disease Company Coalition shows. That could mean $4 billion in missed revenue for already cash-strapped biotechs.
FEATURED STORIES
An inconsistent boom-and-bust cycle funding environment for early-stage biotech innovations and burdensome regulation threaten the U.S.’s half-century-long dominance in the biotech sector.
Acadia Pharma’s Catherine Owen Adams is one of the founders of a group of small- to mid-cap biotechs advocating against a ‘peanut butter blanket’ approach to drug pricing for small companies.
Former European Trade Commissioner Phil Hogan and former US Senator Richard Burr, speaking on a panel at the J.P. Morgan Healthcare Conference, pushed to see a larger picture beyond the Trump administration’s year of chaos and confusion.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
NAYZILAM was approved to treat frequent seizure cluster episodes in epilepsy patients.
Project Facilitate is a pilot project to create a single point of contact for the FDA’s oncology expanded access requests.
Pfizer’s Fragmin was approved to reduce the recurrence of VTE in patients one month of age or older.
More than 12,000 buyers visit 2019 fair, up 8% on last year
Probiodrug AG announced today its first quarter business update for the period ending March 31, 2019.
Pharming Group N.V. presents its (unaudited) interim financial report for the first quarter ended 31 March 2019.
The plaintiffs allege that Gilead and other companies used anticompetitive tactics to keep prices artificially high for their respective HIV treatments.
Purdue, Bristol-Myers Squibb and Apotex have been singled out in opioid-related lawsuits in Canada.
The combination of Venclexta and Gazyva was rapidly approved by the FDA under a pilot program.
Promore Pharma AB (publ) publishes its Interim report for the first quarter 2019 at 13.00 CET on 21 May 2019.